Efficacy of oral etoposide in patients with platinum and taxane-resistant intensively pretreated ovarian cancer

被引：0
|
作者：
Makhnova, Elena V. [1 ]
Gershanovich, Michael L. [1 ]
机构：
[1] NN Petrov Oncol Res Inst, St Petersburg, Russia
来源：
ANNALS OF ONCOLOGY | 2004年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：128 / 129
页数：2
相关论文
共 50 条
  • [1] Phase II study of irinotecan plus oral etoposide in patients with platinum and taxane-resistant ovarian cancer.
    Nishio, S
    Sugiyama, T
    Shoji, T
    Kitagawa, R
    Ushijima, K
    Kamura, T
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 479S - 479S
  • [2] Pilot study evaluating the efficacy and toxicity of irinotecan plus oral etoposide for platinum- and taxane-resistant epithelial ovarian cancer
    Nishio, Shin
    Sugiyama, Toru
    Shouji, Tadahiro
    Yoshizaki, Akira
    Kitagawa, Ryo
    Ushijima, Kimio
    Kamura, Toshiharu
    GYNECOLOGIC ONCOLOGY, 2007, 106 (02) : 342 - 347
  • [3] Efficacy of a Covalent Microtubule Stabilizer in Taxane-Resistant Ovarian Cancer Models
    Yee, Samantha S.
    Risinger, April L.
    MOLECULES, 2021, 26 (13):
  • [4] Phase II trial of oral etoposide plus IV irinotecan for patients with platinum-resistant and taxane-pretreated ovarian cancer (JCOG0503)
    Matsumoto, Koji
    Katsumata, Noriyuki
    Shibata, Taro
    Takano, Tadao
    Nishimura, Ryuichiro
    Kasamatsu, Takahiro
    Satoh, Toyomi
    Saitoh, Motoaki
    Nishimura, Sadako
    Matsumura, Noriomi
    Kobayashi, Hiroaki
    Aihara, Satomi
    Nogawa, Takayoshi
    Saito, Toshiaki
    Ushijima, Kimio
    Fukuda, Haruhiko
    Konishi, Ikuo
    Kamura, Toshiharu
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [5] Phase II trial of oral etoposide plus intravenous irinotecan in patients with platinum-resistant and taxane-pretreated ovarian cancer (JCOG0503)
    Matsumoto, Koji
    Katsumata, Noriyuki
    Shibata, Taro
    Satoh, Toyomi
    Saitou, Motoaki
    Yunokawa, Mayu
    Takano, Tadao
    Nakamura, Kenichi
    Kamura, Toshiharu
    Konishi, Ikuo
    GYNECOLOGIC ONCOLOGY, 2015, 136 (02) : 218 - 223
  • [6] Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer
    Verschraegen, C. F.
    Czok, S.
    Muller, C. Y.
    Boyd, L.
    Lee, S. J.
    Rutledge, T.
    Blank, S.
    Pothuri, B.
    Eberhardt, S.
    Muggia, F.
    ANNALS OF ONCOLOGY, 2012, 23 (12) : 3104 - 3110
  • [7] Focal Adhesion Kinase in Ovarian Cancer: A Potential Therapeutic Target for Platinum and Taxane-Resistant Tumors
    Levy, Arkene
    Alhazzani, Khalid
    Dondapati, Priya
    Alaseem, Ali
    Cheema, Khadijah
    Thallapureddy, Keerthi
    Kaur, Paramjot
    Alobid, Saad
    Rathinavelu, Appu
    CURRENT CANCER DRUG TARGETS, 2019, 19 (03) : 179 - 188
  • [8] Weekly cisplatin and oral etoposide for platinum resistant ovarian cancer
    Clive, S
    Storey, DJ
    Cullen, C
    Dixon, N
    Rye, T
    MacKean, M
    Smyth, JF
    Gabra, H
    BRITISH JOURNAL OF CANCER, 2004, 91 : S40 - S40
  • [9] Phase II Study of Oral Etoposide and Intravenous Irinotecan for Patients with Platinum-resistant and Taxane-pretreated Ovarian Cancer: Japan Clinical Oncology Group Study 0503
    Matsumoto, Koji
    Katsumata, Noriyuki
    Saito, Isamu
    Shibata, Taro
    Konishi, Ikuo
    Fukuda, Haruhiko
    Kamura, Toshiharu
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 42 (03) : 222 - 225
  • [10] Efficacy and safety of combined anlotinib-oral etoposide treatment for patients with platinum-resistant ovarian cancer
    Huang, Shuai
    Sheng, Guihua
    Lv, Qiubo
    Li, Ye
    Meng, Qingwei
    Gao, Xuexiao
    Shang, Zhiyuan
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2024, 35 (06)
12345